A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors.

Deirdre Jill Cohen,Shubham Pant,Bert H. O’Neil,Jill M. Marinis,James Winnberg,Christoph Matthias Ahlers,Justin Callaway,Chetan Rathi,Andre P. Acusta,Adeline Verticelli,John Bertin,James F. Smothers

A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors.

2019

Deirdre Jill Cohen
Shubham Pant
Bert H. O’Neil
Jill M. Marinis
James Winnberg
Christoph Matthias Ahlers
Justin Callaway
Chetan Rathi
Andre P. Acusta
Adeline Verticelli
John Bertin
James F. Smothers

TPS4165Background: The immunosuppressive myeloid infiltrate characteristic of the tumor microenvironment in pancreatic cancer represents a major therapeutic barrier in this disease. Modulation of t...

Keywords:

Oncology
Pembrolizumab
Pathology
Internal medicine
Medicine
Disease
Tumor microenvironment
Cancer research
Pancreatic cancer
phase i ii
Myeloid

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations